TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers

Impact · against what's priced in

TuHURA Biosciences (HURA) is advancing its TBS-2025 VISTA-inhibiting antibody into clinical trials for AML, representing a new value driver for the company. The potential for an accelerated approval pathway and a compressed Phase 1b/2 timeline increases the probability of faster commercialization in a high-unmet-need market.

HURA+0.60

No priced-in read yet